Citadel Advisors
VERA icon

Citadel Advisors’s Vera Therapeutics VERA Stock Holding History

Citadel Advisors’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.3M Sell
429,761
-347,727
-45% -$15M ﹤0.01% 2503
2025
Q4 		$39.4M Sell
777,488
-837,850
-52% -$29.8M 0.01% 1641
2025
Q3 		$46.9M Buy
1,615,338
+1,052,472
+187% +$24.3M 0.01% 1449
2025
Q2 		$13.3M Buy
562,866
+351,071
+166% +$7.89M ﹤0.01% 2658
2025
Q1 		$5.09M Buy
211,795
+156,989
+286% +$5.04M ﹤0.01% 3843
2024
Q4 		$2.32M Buy
54,806
+51,736
+1,685% +$2.29M ﹤0.01% 5323
2024
Q3 		$136K Sell
3,070
-1,581
-34% -$60K ﹤0.01% 10692
2024
Q2 		$168K Sell
4,651
-22,311
-83% -$885K ﹤0.01% 10177
2024
Q1 		$1.16M Sell
26,962
-12,685
-32% -$452K ﹤0.01% 6616
2023
Q4 		$610K Sell
39,647
-4,647
-10% -$59K ﹤0.01% 7669
2023
Q3 		$607K Buy
+44,294
New +$760K ﹤0.01% 7633
2023
Q2 		– Sell
-775,792
Closed -$7.01M – 15295
2023
Q1 		$6.02M Sell
775,792
-1,215,681
-61% -$9.38M ﹤0.01% 3505
2022
Q4 		$38.5M Hold
1,991,473
– – 0.01% 1336
2022
Q3 		$42.4M Sell
1,991,473
-131,378
-6% -$2.46M 0.01% 1196
2022
Q2 		$28.9M Buy
2,122,851
+33,331
+2% +$582K 0.01% 1496
2022
Q1 		$49.1M Buy
2,089,520
+356,338
+21% +$7.67M 0.01% 1134
2021
Q4 		$46.3M Buy
1,733,182
+4,834
+0.3% +$107K 0.01% 1230
2021
Q3 		$29.1M Sell
1,728,348
-10,345
-0.6% -$185K 0.01% 1598
2021
Q2 		$22.2M Buy
+1,738,693
New +$27M 0.01% 1955

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors's VERA Position: Q1 2026 in Review

Citadel Advisors reduced its Vera Therapeutics (VERA) stake by 45% in Q1 2026, selling an estimated $15M and leaving 429,761 shares worth $17.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2503.

Citadel Advisors first reported a position in VERA in Q2 2021 and has held it in 19 quarters since. The position peaked at $49.1M in Q1 2022. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

  • Citadel Advisors held 429,761 shares of Vera Therapeutics worth $17.3M as of Q1 2026.
  • Citadel Advisors sold 347,727 Vera Therapeutics shares in Q1 2026, an estimated $15M.
  • Vera Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2503 holding.
  • Citadel Advisors first reported a position in Vera Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Citadel Advisors's Vera Therapeutics position peaked at $49.1M in Q1 2022.
  • 229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.